Allarity Therapeutics CEO to present at Precision Medicine Forum Europe 2026

Allarity Therapeutics, Inc.

CEO Thomas Jensen will speak on May 11, 2026, in Stockholm, Sweden at Precision Medicine Forum Europe 2026.
Presentation will cover stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, and the Stenoparib DRP biomarker.
Allarity is a Phase 2 clinical-stage company developing stenoparib for cancer; no new clinical data or financial results announced.
A corporate presentation furnished as Exhibit 99.1 will be used in investor meetings beginning May 11, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.